11 completed. 11 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 11 |
| Phase 3 | 2 | Completed 2 |
Follow Pharming Technologies B.V.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Leniolisib for Immune Dysregulation in CVID Leniolisib - Common Variable Immunodeficiency (CVID) | Phase 2 | Completed | Pharming Technologies B.V. | 27 | 2025-02-12 | 2026-09-18 |
| Leniolisib for Immune Dysregulation in PIDs Leniolisib - Primary Immunodeficiency Disorders (PIDs) | Phase 2 | Completed | Pharming Technologies B.V. | 13 | 2024-10-21 | 2026-10-19 |
| Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation Conestat alfa (Ruconest®), NaCl 0.9%) - Acute Ischemic Stroke, Acute Renal Injury | Phase 2 | Completed | University Hospital, Basel, Switzerland | 141 | 2022-03-16 | 2026-04-22 |
| Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19 Ruconest - Confirmed Coronavirus Disease | Phase 2 | Completed | Pharming Technologies B.V. | 38 | 2020-11-30 | 2024-02-16 |
| Recombinant Human C1 Esterase Inhibitor in the Prevention of Contrast-induced Nephropathy in High-risk Subjects Conestat alfa, Sodium chloride 0.9% - Acute Kidney Injury | Phase 2 | Completed | University Hospital, Basel, Switzerland | 80 | 2017-01-01 | 2018-08-08 |
| A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor Recombinant human C1 inhibitor, Placebo - Hereditary Angioedema | Phase 2 | Completed | Pharming Technologies B.V. | 32 | 2014-12-01 | 2017-12-08 |
| Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients rhC1INH - Hereditary Angioedema | Phase 2 | Completed | Pharming Technologies B.V. | 57 | 2012-01-17 | 2024-03-29 |
| A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration Recombinant Human C1 Inhibitor - Genetic Disorders, Hereditary Angioedema | Phase 2 | Completed | Pharming Technologies B.V. | 25 | 2009-06-01 | 2018-06-26 |
| Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema Recombinant Human C1 Inhibitor, placebo - Hereditary Angioedema, Angioneurotic Edema | Phase 2 / Phase 3 | Completed | Pharming Technologies B.V. | 77 | 2005-07-01 | 2013-02-22 |
| Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema i.v. recombinant human C1 inhibitor - Genetic Disorders | Phase 2 / Phase 3 | Completed | Pharming Technologies B.V. | 14 | 2004-04-01 | 2013-02-22 |
| Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema i.v. recombinant human C1 inhibitor - Genetic Disorders | Phase 2 | Completed | Pharming Technologies B.V. | 14 | 2003-06-01 | 2013-04-25 |
Angioedemas, Hereditary (4) · Genetic Diseases, Inborn (3) · Acute Kidney Injury (2) · Angioedema (2) · Aortic Valve Stenosis (1) · Common Variable Immunodeficiency (1) · Heart Valve Diseases (1) · Inflammation (1) · Ischemic Stroke (1) · Primary Immunodeficiency Diseases (1) · Reperfusion Injury (1)
conestat alfa (7) · Sodium Chloride (4) · Complement C1 Inhibitor Protein (3) · leniolisib (2)
United States (5) · Netherlands (4) · Romania (3) · Czechia (2) · Italy (2) · North Macedonia (2) · Switzerland (2) · Canada (1) · Germany (1) · Hungary (1) · Israel (1) · Poland (1) · Serbia (1) · Slovakia (1) · Spain (1)
Anurag Relan, MD (2) · Jan Nuijens, MD, PhD (2) · Bruno Giannetti, MD (1) · Gulbu Uzel, M.D. (1) · Jonathan Bernstein, MD (1) · Michael Osthoff, M.D. (1) · Michael Osthoff, Prof. Dr. med. (1) · Raban Jeger, Prof. Dr. med. (1)
PMID 20920772, PMID 23535096, PMID 28284978, PMID 28754491, PMID 30993784, PMID 32171721, PMID 36326435, PMID 41608120, PMID 42159953